Cellphire, Inc. announced today that Rafael Jorda has joined the company as Vice President of Research & Development.
Mr. Jorda is an internationally experienced scientific leader with more than 25 years of experience in private and public company management spanning three continents. He has managed the R&D, Intellectual Property, Production, and Business Development operations of companies in the pharmaceutical and biotech industries. He was a co-founder of Flamel Technologies (FLML) and led research and manufacturing, helping build it into a successful, publicly traded company. Previously, Mr. Jorda worked in the polymer research group of Rhône-Poulenc. He holds an MS in Chemical Engineering from Virginia Tech.
“Rafael brings a tremendous amount of experience to the table in managing pharmaceutical research and development at a very high level,” said Cellphire’s CEO Stephen Willard. “His addition to the Cellphire team allows us to pursue multiple R&D initiatives to leverage our platform technology.”
About Cellphire
Cellphire, Inc. is a biotechnology company developing next-generation therapeutics. The company is applying its proprietary cell stabilization technology to all cell types, including platelets, to develop lifesaving products. Its lead product is Thrombosomes®, a freeze-dried hemostatic derived from human platelets. Cellphire’s technology has potential applications across a wide range of medical applications from trauma to wound care, imaging, targeted drug delivery, and regenerative medicine. For more information, visit www.cellphire.com.
Contacts:
Media
Sharon Burns
Director, Communications
sburns@cellphire.com
Investor Relations
Tom Dann
Chief Investment Officer
tdann@cellphire.com